Galderma
Galderma is a global dermatology company and the principal brand and commercial context for Sculptra in Injectable Index. Galderma should not automatically be described as every product-level manufacturer or approval holder: FDA records identify Q-Med AB as the Sculptra applicant, while local labels can assign additional legal roles.
Company reference
Section titled “Company reference”| Field | Galderma |
|---|---|
| Injectable Index relationship | Commercial brand context for Sculptra |
| Headquarters | Zug, Switzerland |
| Public status | Listed on the SIX Swiss Exchange |
| Ticker | GALD |
| First trading date | March 22, 2024 |
| Relevant business category | Injectable Aesthetics |
Galderma’s investor site confirms that Galderma Group AG shares have traded on the SIX Swiss Exchange under GALD since March 22, 2024 (Galderma share information 🔗). The company lists its headquarters in Zug, Switzerland (Galderma contact information 🔗).
Product-role matrix
Section titled “Product-role matrix”| Product | Brand and commercial company | Developer or origin | Legal manufacturer | Regulatory applicant or approval holder |
|---|---|---|---|---|
| Sculptra | Galderma | Product history predates the current Galderma public-company structure | Verify from the applicable IFU | Q-Med AB is the FDA PMA applicant |
This matrix prevents four roles from being flattened into “made by Galderma.”
Galderma’s global Sculptra page establishes the current brand relationship (Galderma Sculptra 🔗). The FDA PMA database identifies Q-Med AB as applicant for Sculptra records (FDA PMA history 🔗).
Why Galderma matters to the product graph
Section titled “Why Galderma matters to the product graph”Galderma controls the current global commercial narrative, product education, and much of the accessible official product documentation for Sculptra. Its role is especially relevant for:
- current international IFU access
- formulation and preparation updates
- country launches and availability
- new indication or certification announcements
- portfolio and market context
These sources are authoritative for company position and product instructions when the document applies to the market being described. Promotional claims still need independent or regulatory support before becoming comparative clinical conclusions.
Regulatory and market interpretation
Section titled “Regulatory and market interpretation”Sculptra’s regulatory identity is regional. A Galderma global announcement can establish a launch or company milestone, but it should not replace:
- FDA approval records for the United States
- a current regional IFU
- the applicable legal manufacturer
- the local approval holder
- local indication and contraindication wording
Galderma’s 2025 annual report states that Sculptra launched in China and received European certification for expanded body indications during 2025 (Galderma 2025 annual report 🔗). Those are distinct regional developments, not a universal change in the Sculptra label.
Selective timeline
Section titled “Selective timeline”| Date | Event | Why it changes interpretation |
|---|---|---|
| March 22, 2024 | Galderma Group AG began trading on SIX under GALD | Establishes current public-company status |
| 2025 | Sculptra launched in China | Expands the product’s regional commercial context |
| 2025 | Galderma reported European certification for expanded Sculptra body indications | Adds a regional regulatory milestone without changing other markets automatically |
| 2026 | Galderma continued global Sculptra positioning and published current product material | Confirms the brand remains a core injectable-aesthetics franchise |
Company-page boundaries
Section titled “Company-page boundaries”Do not use Galderma’s portfolio ownership to infer:
- one global Sculptra indication
- one legal manufacturer
- identical preparation in every market
- FDA approval for body use
- clinical superiority over another PLLA product
Related pages
Section titled “Related pages”- Regional regulation separates Q-Med’s US applicant role from EU certification and Korean product information.
- Sculptra contains the product-level composition, preparation, and approval context.
- PLLA places Sculptra in its material family.
- Sinclair provides the nearest initial company comparison through Lanluma.
- Collagen Stimulators maps the full reference cluster.